Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data

被引:0
作者
Schwartz, J. J. [1 ]
Wilson, S. [1 ]
Shi, F. [1 ]
Elsouda, D. [1 ]
Undre, N. [2 ]
Kumar, M. S. A. [1 ]
机构
[1] Astellas Pharma Global Dev Inc, Med Affairs, 1 Astellas Way, Northbrook, IL 60062 USA
[2] Astellas Pharma Global Dev Inc, Med Affairs, Chertsey, England
关键词
TWICE-DAILY PROGRAF; AFRICAN-AMERICAN; RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; INTRAPATIENT VARIABILITY; RACIAL-DIFFERENCES; BLOOD-LEVELS; RECIPIENTS; IMMUNOSUPPRESSION; PHARMACOKINETICS;
D O I
10.1016/j.transproceed.2018.08.050
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Black kidney transplant patients experience inferior outcomes compared with other ethnicities. Because scrutiny is required when immunosuppressant drugs are used in such at-risk populations, we report the first large-scale clinical efficacy data assessing prolonged-release tacrolimus (PR-T) in black de novo kidney transplant patients. Methods and materials. We used logistic regression and proportionate hazards to compare a composite outcome measure (biopsy-proven acute rejection, graft loss, mortality, and loss to follow-up) in black and white patients in treatment groups longer than 24 weeks, from 3 large Phase III randomized controlled trials. Secondary endpoints included tacrolimus trough concentration, dose, and estimated glomerular filtration rate. Results. The study included 2162 patients whose treatments belonged to two categories (immediate-release tacrolimus: 77 black patients, 721 white patients; and PR-T: 87 black patients, 1277 white patients). Despite demographic factors generally predictive of worse outcomes, efficacy failure among black patients who received PR-T was non-inferior to that among white patients who received either therapy. Compared with immediate-release tacrolimus, black patients who received PR-T achieved stable tacrolimus concentrations 2.5 times faster (21 vs 56 days, P =.04), and more achieved stable target concentrations (76.7% vs 69.3%). Treatment-emergent adverse events were consistent with those reported separately in pivotal trials. Conclusions. Overall, black patients who received PR-T achieved non-inferior outcomes compared to white patients, despite higher pretransplant risk among black patients. Moreover, PR-T improved the time to achieve, and the likelihood of reaching, stable therapeutic concentrations among black patients, suggesting that PR-T could improve the consistency of tacrolimus exposure in this patient population.
引用
收藏
页码:3283 / 3295
页数:13
相关论文
共 51 条
  • [1] OSAKA Trial: A Randomized, Controlled Trial Comparing Tacrolimus QD and BD in Kidney Transplantation
    Albano, Laetitia
    Banas, Bernhard
    Klempnauer, Juergen L.
    Glyda, Maciej
    Viklicky, Ondrej
    Kamar, Nassim
    [J]. TRANSPLANTATION, 2013, 96 (10) : 897 - 903
  • [2] Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen
    Alloway, R
    Steinberg, S
    Khalil, K
    Gourishankar, S
    Miller, J
    Norman, D
    Hariharan, S
    Pirsch, J
    Matas, A
    Zaltzman, J
    Wisemandle, K
    Fitzsimmons, W
    First, MR
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 867 - 870
  • [3] [Anonymous], 2015, ENV TACR EXT REL TAB
  • [4] [Anonymous], 2018, PROGRAF PACK INS
  • [5] Astagraf XL, 2018, AST XL TACR EXT REL
  • [6] Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone
    Beermann, Kristi J.
    Ellis, Matthew J.
    Sudan, Debra L.
    Harris, Matthew T.
    [J]. CLINICAL TRANSPLANTATION, 2014, 28 (07) : 762 - 767
  • [7] Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial
    Budde, Klemens
    Zeier, Martin
    Witzke, Oliver
    Arns, Wolfgang
    Lehner, Frank
    Guba, Markus
    Jacobi, Johannes
    Kliem, Volker
    Reinke, Petra
    Hauser, Ingeborg A.
    Vogt, Bruno
    Stahl, Rolf
    Rath, Thomas
    Duerr, Michael
    Paulus, Eva-Maria
    May, Christoph
    Porstner, Martina
    Sommerer, Claudia
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (06) : 1060 - 1070
  • [8] RACIAL-DIFFERENCES IN THE SURVIVAL OF CADAVERIC RENAL-ALLOGRAFTS - OVERRIDING EFFECTS OF HLA MATCHING AND SOCIOECONOMIC-FACTORS
    BUTKUS, DE
    MEYDRECH, EF
    RAJU, SS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (12) : 840 - 845
  • [9] CERVELLI M, 2012, AUST J PHARM, V93, P83
  • [10] A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)
    Durrbach, A.
    Pestana, J. M.
    Pearson, T.
    Vincenti, F.
    Garcia, V. D.
    Campistol, J.
    del Carmen Rial, M.
    Florman, S.
    Block, A.
    Di Russo, G.
    Xing, J.
    Garg, P.
    Grinyo, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (03) : 547 - 557